Valeant Pharmaceuticals Inc. issued a statement Monday afternoon in response to a report that its former chief executive and CFO may face criminal charges, though the statement said little of consequence. Valeant, which has faced intense scrutiny for more than a year stemming from the prices it charges for medicine and its relationship with a mail-order pharmacy, acknowledged again that it is under investigation from the U.S. Attorney’s Office in New York and that it is cooperating with that inquiry. “We do not comment on rumors about investigations, and cannot comment on or speculate about the possible course of any ongoing investigation,” the company stated. Valeant shares dove more than 12% Monday, with the decline occurring swiftly after the original Bloomberg News report was released; the stock gained about 2% in late trading.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News